QLIF-47. HEALTH RELATED QUALITY OF LIFE AND NEUROLOGICAL DETERIORATION FREE SURVIVAL IN INTELLANCE 2/EORTC TRIAL 1410, A RANDOMIZED PHASE II STUDY ON ABT414 IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA

BACKGROUND: Treatment options for recurrent glioblastoma are limited. 45-50% of glioblastoma show EGFR amplification. ABT-414 is a tumor-specific antibody-drug conjugate (ADC) combining an antibody (ABT-806) targeting a unique conformation of EGFR bound to monomethyl auristatin F (MMAF), a microtubu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Clement, Paul, van den Bent, Martin, Eoli, Marica, Sepulveda, Juan Manuel, Walenkamp, Annemiek, Frenel, Jean-Sebastien, Franceschi, Enrico, Weller, Michael, Chinot, Olivier, de Vos, Filip, Whenham, Nicolas, Sanghera, Paul, Looman, Jim, Lee, Ho-Jin, de Geus, Jan-Peter, Nuyens, Sarah, Spruyt, Maarten, Gorlia, Thierry, Coens, Corneel, Golfinopoulos, Vassilis
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692867/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.854
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados